[1]
|
S. H. Forshdahl, K. Singh, S. Solberg and B. K. Jacobsen, “Risk Factors for Abdominal Aortic Aneurysms a 7-Year Prospective Study: The Tromso Study, 1994-2001,” Circulation, Vol. 119, 2009, pp. 2202-2208.
doi:10.1161/CIRCULATIONAHA.108.817619
|
[2]
|
K. Singh, K. H. Bonaa, B. K. Jacobsen, L. Bjork and S. Solberg, “Prevalence of and Risk Factors for Abdominal Aortic Aneurysms in a Population—Based Study: The Tromso Study,” American Journal of Epidemiology, Vol. 154, No. 3, 2001, pp. 236-244. doi:10.1093/aje/154.3.236
|
[3]
|
D. Reed, C. Reed, G. Stemmermann and T. Hayashi, “Are Aort?c Aneurysms Caused by Atherosclerosis?” Circulation, Vol. 85, 1992, pp. 205-211.
|
[4]
|
A. J. Lee, F. G. Fowkes, M. N. Carson, G. C. Leng and P. L. Allan, “Smoking, Atherosclerosis and Risk of Abdominal Aortic Aneurysm,” European Heart Journal, Vol. 18, No. 4, 1997, pp. 671-676.
|
[5]
|
S. Giordano, F. Biancari, P. Loponen, J. Wistbacka and M. Luther, “Preoperative Haemodynamic Parameters and the Immediate Outcome after Open Repair of Ruptured Abdominal Aortic Aneurysms,” Interactive Cardiovascular Thoracic Surgery, Vol. 9, 2009, pp. 491-493.
|
[6]
|
T. Wolff, D. Baykut, H. R. Zerkowski, P. Stierli and L. Gurke, “Combined Abdominal Aortic Aneurysm Repair and Coronary Artery Bypass: Presentation of 13 Cases and Review of the Literature,” Annals of Vascular Surgery, Vol. 20, No. 1, 2006, pp. 23-29.
doi:10.1007/s10016-005-9324-9
|
[7]
|
I. Kantonen, M. Lepantalo, J. P. Salenius, S. Matzke, M. Luther and K. Ylonen, “Mortality in Abdominal Aortic Aneurysm Surgery: The Effect of Hospital Volume, Patient Mix and Surgeon’s Case Load,” European Journal of Vascular and Endovascular Surgery, Vol. 14, No. 5, 1997, pp. 375-379. doi:10.1016/S1078-5884(97)80287-0
|
[8]
|
T. Juvonen, F. Biancari, J. Rimpilainen, V. Anttila, M. Pokela, V. Vainionpaa, P. Romsi and K. Kiviluoma, “Determinants of Mortality after Hypothermic Circulatory Arrest in a Chronic Porcine Model,” European Journal of Cardio—Thoracic Surgery, Vol. 20, No. 4, 2001, pp. 803-810.
|
[9]
|
J. Levijoki, P. Pollesello, J. Kaivola, C. Tilgmann, T. Sorsa, A. Annila, I. Kilpelainen and H. Haikala, “Further Evidence for the Cardiac Troponin C Mediated Calcium Sensitization by Levosimendan. Structure—Response and Binding Analysis with Analogs of Levosimendan,” Journal of Molecular and Cellular Cardiology, Vol. 32, No. 3, 2000, pp. 479-491. doi:10.1006/jmcc.1999.1093
|
[10]
|
Z. Papp, K. Csapo, P. Pollesello, H. Haikala and I. Edes, “Pharmacological Mechanisms Contributing to the Clinical Efficacy of Levosimendan,” Cardiovasc Drug Review, Vol. 23, No. 1, 2005, pp. 71-98.
doi:10.1111/j.1527-3466.2005.tb00158.x
|
[11]
|
D. P. Figgit, P. S. Gillies and K. L. Goa, “Levosimendan,” Drugs, Vol. 61, 2001, pp. 613-627.
doi:10.2165/00003495-200161050-00006
|
[12]
|
M. Bayram, L. De Luca, B. M. Massie and M. Gheorghiade, “Dobutamine Milrinone and Dopamine in Acute Heart Failure Syndromes: A Reassessment,” American Journal of Cardiology, Vol. 96, No. 6, 2005, pp. 47-58.
doi:10.1016/j.amjcard.2005.07.021
|
[13]
|
L. D. Caldicott, K. Hawley, R. Heppel, P. A. Woodmansey and K. S. Channer, “Intravenous Enoximone or Dobutamine for Severe Heart Failure after Acute Miyocardial Infarction: A Randomized Double-Blind Trial,” European Heart Journal, Vol. 14, No. 5, 1993, pp. 696-700. doi:10.1093/eurheartj/14.5.696
|
[14]
|
A. D. Michaels, B. McKeown, M. Kostal, K. T. Vakharia, M. V. Jordan, I. L. Gerber, E. Foster and K. Chatterjee, “Effects of Intravenous Levosimendan on Human Coronary Vasomotor Regulation, Left Ventricular Wall Stress, and Myocardial Oxygen Uptake,” Circulation, Vol. 111, 2005, pp. 1504-1509.
doi:10.1161/01.CIR.0000159252.82444.22
|